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BIOMARKERS FOR AGING 
RELATED APPLICATIONS 
This application a Divisional of US. application Ser. No. 
10/486,706, ?led Aug. 13, 2004, noW abandoned Which is a 
US. National Phase under 35 USC §371 of International 
Application No. PCT/ US2002/ 25 607, ?led on Aug. 13, 2002, 
claiming priority of US. Provisional Application No. 60/311, 
343, ?led Aug. 13, 2001, the entire contents of each of Which 
are hereby incorporated by reference. 
STATEMENT OF GOVERNMENT INTEREST 
This invention has been made in part With government 
support under grants AG04542, AG10836, AG18228 and 
AG14979 from the National Institute on Aging, and by 
MH59891. The government of the United States of America 
may have certain rights in this invention. 
FIELD OF THE INVENTION 
The invention relates generally to genetic algorithms, and 
more particularly to the identi?cation of gene expression 
pro?le biomarkers and therapeutic targets for brain aging. 
BACKGROUND OF THE INVENTION 
Brain aging processes are enormously complex phenom 
ena that affect multiple systems, cell types and pathWays, and 
result in cognitive decline and increased risk of AlZheimer’s 
disease (AD). Land?eld P W et al., J Neurobiol 23: 1247 
1260 (1992). Although several biological mechanisms have 
been putatively linked to brain aging or AlZheimer’s disease, 
including in?ammation, oxidative stress, Ca2+ dyshomeosta 
sis (Land?eld, P W & Pitler T A, Science 226: 1089-1092 
(1984); Land?eld P W et al., J Neurobiol 23: 1247-1260 
(1992)), mitochondrial dysfunction and chronic exposure to 
adrenal stress hormones (Land?eld P W et al., Science 214: 
581-584 (1981); Porter N M & Land?eld P W, Nature Neu 
rosci 1: 3-4 (1998)), the speci?c mechanisms andpathWays, if 
any, through Which they are linked to impaired brain function 
are not understood. 
It is Widely thought that gene expression changes contrib 
ute to many aspects of declining function With aging. Finch C 
E, Longevity, Senescence and the Genome, 37-42 (Univ. Chi 
cago Press, Chicago, 1990). It is also thought that gene 
expression changes are important for processing and storage 
of memory. HoWever, not all genes that change expression in 
the brain With aging are thought to be important for cognition. 
Gene-expression changes that speci?cally contribute to 
age-related memory decline should selectively change With 
brain aging and should be correlated speci?cally With mea 
sures of age-associated cognitive decline; that is, a subset of 
the full set of aging-dependent genes should also correlate 
With age-related cognitive decline. See, Lockhart D J & Bar 
loW C, Nat Rev Neurosci 2: 63-68 (2001) and Mimics K, Nat 
Rev Neurosci 2: 444-447 (2001). 
If a subset of age-dependent genes also shoWs expression 
patterns directly correlated With age-related memory decline, 
then such a subset of “aging and cognition-related genes” 
(ACGs) Would be extremely helpful as biological indexes 
(“biomarkers”) for assessing or diagnosing the degree of 
age-related cognitive impairment in individual subjects. In 
turn, the ability to measure aging-related cognitive impair 
ment quantitatively is essential for discovering neW therapeu 
tic targets, and developing neW strategies and pharmaceutical 
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2 
compounds for counteracting normal age-related cognitive 
decline and/or age-related neurodegenerative diseases, 
including AlZheimer’s disease (AD) or Parkinson’s disease 
(PD). 
Identifying ACGs in any mammalian species therefore, 
might have great therapeutic usefulness. Moreover, because 
of the Well-established homologies of most genes across 
mammalian species and because of the clear similarities in 
patterns of brain aging and cognitive decline across species, 
identi?cation in any mammal Would have human health 
implications. Furthermore, because the primary risk factor 
for AlZheimer’s disease and Parkinson’s disease is aging 
itself, therapeutic approaches developed for aging-related 
cognitive impairment should also help ameliorate cognitive 
decline from age-related neurodegenerative disease. Thus, 
there is a clear need for identifying ACGs but, to date, such 
genes have not been discovered for any mammal. 
Gene microarray technology provides a poWerful approach 
for unraveling the complex processes of aging. To date, hoW 
ever, its impact has been limited by statistical problems, small 
sample siZes, and dif?culty in assessing functional relevance. 
Moreover, studies that have examined gene expression during 
brain aging using microarrays have not used sample siZes 
large enough to provide adequate statistical poWer for formal 
statistical testing. Lee C K et al., Nature Genetics 25: 294-297 
(2000); Jiang C H et al., Proc NatlAcad Sci USA 98: 1930 
1934 (2001) Therefore, even the genes they have reported to 
change With aging have not been validated by accepted sta 
tistical criteria. 
The extremely large data sets generated by microarrays 
pose formidable bioinformatics and resource problems that 
have to date limited the impact of this powerful technology. 
Because of these di?iculties, most microarray studies have 
relied on simple fold change comparisons in small samples. 
HoWever, neither fold change analyses nor the small sample 
protocols Widely used alloW the direct estimates of variance 
necessary for de?ning type I error (false positives). In addi 
tion, fold change criteria, by de?nition, select for large 
changes. Therefore, they exhibit loW detection sensitivity 
(high false negatives, or type II error), and are unable to 
identify the modest changes that often characterize function 
ally important (and, therefore, tightly regulated) genes. The 
inability to assign typeI error is a particularly critical problem 
for microarray studies because the thousands of comparisons 
of gene expression in such analyses greatly increase the 
expected false positives. For example, even if group siZes 
Were suf?cient for formal statistical analyses, and 5000 gene 
transcripts Were each tested by t-test for differences betWeen 
tWo conditions at p§0.05, the false positive rate is equal to the 
p-value and, consequently, 5% of the 5000 tested transcripts 
(250) Would be expected to be found signi?cant by chance 
alone. 
Although microarray studies have some important offset 
ting advantages that improve statistical con?dence (e.g., co 
regulation of genes Within a functional group), there is 
increasing recognition that microarray experiments should 
generally meet the same statistical standards as other biologi 
cal experiments or, at least, should systematically estimate 
the degree of statistical uncertainty. Several strategies to 
improve statistical con?dence have been developed for small 
sample microarray studies, but these generally rely on indi 
rect estimates of variance and/or greatly sacri?ce sensitivity 
(i.e., stringent p-values). 
Another highly important problem of microarray studies is 
that of determining Which of the hundreds of expression 
changes that may be observed are likely to be functionally 
relevant. Correlation analysis is one quantitative approach to 
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linking gene expression With function, although it also 
requires relatively large sets of independent samples. Expres 
sion-function correlations ful?ll a key prediction of a causal 
relationship (i.e., that causally related variables should co 
vary) and therefore, can serve as a valuable tool for the iden 
ti?cation of candidate functionally relevant genes. Nonethe 
less, there have been feW correlation studies attempting to 
link cognitive dysfunction With univariate gene expression 
patterns across individual subjects, much less using the mas 
sive amounts of data generated in microarray analyses. 
SUMMARY OF THE INVENTION 
The invention provides a statistical and functional correla 
tion strategy to identify changes in cellular pathWays speci? 
cally linked to impaired cognitive function With aging. The 
bioinformatics and functional correlation strategy improves 
the poWer of microarray analyses and provides the ability to 
test Whether alterations in speci?c hippocampal pathWays are 
correlated With aging-related cognitive impairment. The 
invention is useful for application in large, Well-poWered 
groups and for controlling type I error (false positives), 
enhancing detection sensitivity (reducing type II false nega 
tives) and determining Which aging changes in expression are 
most closely correlated With declining brain function. 
Accordingly, the invention provides a method for identify 
ing a biomarker for brain aging, Where the biomarker is a 
polynucleotide or a polypeptide encoded by said polynucle 
otide. The method involves ?rst obtaining a set of polynucle 
otides obtained from a set of brain samples (such as hippoc 
ampal samples), Where the members of the set of brain 
samples Were obtained from members of a set of mammals, 
Wherein the set of mammals contains more than tWo mem 
bers, With at least young, mid-aged and aged members, and 
then identifying the identity and amount of the members of 
the set of polynucleotides present in the brain samples. The 
method then involves the steps of deleting certain non-biom 
arker polynucleotides from the set of polynucleotides, testing 
by a conventional statistical method (such as) for a signi?cant 
effect of aging across the young, mid-aged and aged mem 
bers; and correlating the identity and amount of the members 
of the set of polynucleotides present in the brain samples With 
cognitive performance in behavioral tests. 
By use of the methods of the invention, one skilled in the 
genomics art can identify multiple groups of related genes, 
many representing processes With previously unrecogniZed 
relationships to aging and/ or cognitive dysfunction. Thus, the 
invention also provides compositions of matter comprising 
sets of genes, expressed sequence tags (ESTs), polynucle 
otides and polypeptides encoded by said polynucleotides 
identi?ed as being involved in the aging processes. These sets 
usefully result in a statistically validated, comprehensive 
overvieW of mammalian, including human, functional brain 
aging. In particular, the set of genes can be used for the 
diagnosis of human age-related disease, such as an age-re 
lated neurodegenerative condition, including AlZheimer’s 
disease or Parkinson disease. 
The invention provides a set of biomarkers for brain aging, 
Where (a) the set of biomarkers comprises at least tWo mem 
bers; (b) the brain expression patterns of the members of the 
set are signi?cantly altered With aging as determined by a 
conventional statistical method (such as ANOVA or student’ s 
t test), With p<0.05; (c) the brain expression patterns of the 
members of the set are correlated (using a conventional sta 
tistical correlation test, e.g., tested by Pearson’s or Spear 
man’s correlation test) across age groups With cognitive per 
formance in behavioral tests, With a correlation of p<0.05 (or 
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With a more stringent correlation of p<0.0l or p<0.00l) 
betWeen brain expression and cognitive performance; and (d) 
the cognitive performance in behavioral tests signi?cantly 
altered With aging as determined by a conventional statistical 
method. The biomarkers may also correlate With a behavioral 
measure of functional impairment, such as an age-related 
neurodegenerative condition, including AlZheimer’s disease 
or Parkinson’s disease. 
The invention also provides a set of at least tWo biomarkers 
for brain aging, Where Where the brain expression patterns of 
the members of the set are signi?cantly altered With aging as 
measured by a conventional statistical correlation test at a 
signi?cance level of p<0.0l. 
The invention further provides a set of at least tWo biom 
arkers for brain aging, Where the brain expression patterns of 
the members of the set are signi?cantly altered With aging as 
determined by a conventional statistical method, With p<0.05 
(or a more stringent correlation, such as p<0.025, p<0.0l or 
p<0.00l). 
In one example of the invention, rats in three age groups 
(Young, Mid-Aged, Aged) Were characterized on tWo 
memory tasks and each mammal’s hippocampal CA1 region 
Was analyZed by a microarray analysis for gene expression. 
These analyses identi?ed multiple groups of genes, many 
representing pathWays With previously unrecognized rela 
tionships to aging and/or cognitive decline. The analysis 
shoWed that for all groups, the aging changes in expression 
began by mid-life. 
In one aspect of the invention, the knoWn interactions of the 
identi?ed processes suggest an integrative model of speci?c 
cellular cascades that begin in mid-life and eventually impair 
cognitive function and increase neuronal vulnerability. Ini 
tially decreased neuronal activity and/or oxidative metabo 
lism trigger separate but parallel genomic cascades in neurons 
and glia. In neurons, the cascade results in reductions of 
immediate early gene signaling, biosynthesis, synaptogen 
esis and neurite remodeling. In contrast, glia undergo 
increased lipid metabolism and mediate a cycle of demyeli 
nation and remyelination that induces antigen presentation, 
in?ammation, oxidative stress and extracellular restructur 
ing. Intervention studies based on these ?ndings can identify 
the cause and effect interactions among the complex pro 
cesses of brain aging. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a set of bar graphs shoWing age-dependent impair 
ment of memory performance. Male Fischer 344 rats aged 4 
months (Young, n:l0), 13 months (Mid-Aged, n:l0) and 24 
months (Aged, n:l0) Were used. Aged animals exhibited 
signi?cantly reduced performance on 24 hr memory retention 
on both the Morris spatial Water maZe task (SWM; FIG. 1A) 
and object memory task (OMT; FIG. 1B) in comparison to 
either Young or Mid-Aged animals (*p<0.05, **p<0.0l, by 
l-Way ANOVA and Tukey’s post-hoc). As shoWn in the bar 
graph, the Young and Mid-Aged animals did not differ sig 
ni?cantly from each on either the SWM or OMT task. On the 
SWM task (FIG. 1A), higher platform crossings re?ects 
greater retention of the spot Where the platform Was previ 
ously located. For the OMT (FIG. 1B), a higher memory 
index re?ects greater retention of the previously explored 
object, and resultant increased exploration of the novel 
object. 
FIG. 2 is a ?oW chart for a ?ltering and statistical test 
algorithm for identifying primary set of ACGs. The ?oW chart 
also includes the results for an example of the invention. An 
initial set of 8,799 transcript sets contained on the U34A Gene 
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Chip (see, EXAMPLE 2) Was ?ltered prior to statistical test 
ing, to reduce expected false positives. Probe sets Were 
removed if they Were called “absent” (1a.), if they Were 
unknown expressed sequence tags (ESTs) (1b.) or if the dif 
ference betWeen theYoung andAged groups did not comprise 
at least 75% of the maximal normalized age differences (10.). 
Each of the remaining 1,985 transcript (gene) sets Was then 
tested by ANOVA across the three age groups (n:9—10) to 
determine if it changed signi?cantly With aging (2.). Each of 
the 233 genes that changed signi?cantly With age (p§0.025) 
Was then tested across all animals (n:29) for signi?cant 
behavioral correlation With OMT, SWM, or both SWM and 
OMT (Pearson’s; 3a). Furthermore, of the genes that did not 
correlate With behavior, ones that shoWed an ANOVA p 
value§0.001 Were also retained for further analysis (3b). In 
total, 172 genes Were considered, 161 of Which could be 
considered ACGs. 
FIG. 3 is a set of line graphs shoWing correlation of gene 
expression and OMT across individual animals. Behavioral 
correlation is measured across all age groups. For genes that 
decreased With aging, the ?ve best positive correlations (A) 
and for genes that increased With aging, the ?ve best negative 
correlations (B) are shoWn (see Legend: correlation p-values 
in parentheses). Standardized values for both expression and 
OMT performance are shoWn on theY-axis. The animals Were 
ranked for OMT performance on the X-axis, from Worst (1) to 
best (29), and OMT performance Was plotted as a heavy black 
line on both A and B for the purposes of comparison. Genes 
involved in early responses and synaptic remodeling Were 
among the ?ve most highly correlated genes that decreased 
With aging, Whereas those related to actin assembly and 
in?ammation Were among the ?ve most highly correlated 
genes that increased With aging. 
FIG. 4 is a line graph and pie chart insert shoWing func 
tional categories and age course of genes decreased With 
aging. Chronological patterns are shoWn for aging changes 
for ?ve of the eight functional categories (some categories 
Were omitted to improve legibility and because they Were 
highly similar to the ones already depicted). Each gene’s 
expression Was normaliZed prior to calculating category 
mean values. Note that most doWn-regulated categories 
exhibited 250% of mean changes by the Mid-Aged point, 
and shoWed relatively less change betWeen the Mid-Aged and 
Aged animals. No category shoWed a predominantly Mid-to 
Aged pattern of change. The pie-chart insert shoWs propor 
tion of genes that folloWed each of the three possible routes to 
decreased expression With aging. 
FIG. 5 is a line graph and pie chart insert shoWing func 
tional categories and age course of genes increased With 
aging. Chronological patterns are shoWn for aging changes 
for ?ve of the eleven functional categories of behaviorally 
correlated upregulated genes (some categories Were omitted 
to increase legibility and because their pattern of change With 
age Was highly similar to that of categories already depicted). 
Calculations and nomenclature as in FIG. 4. Note that, in 
contrast to the majority of doWnregulated genes (FIG. 4), 
changes in upregulated categories did not tend to level off 
after mid-life but instead shoWed continuing change betWeen 
mid-life and late-life (e.g., a monotonic pattern). Similar pat 
terns Were seen When all upregulated genes are considered 
(Pie-chart inset). 
FIG. 6 is a micrograph shoWing a model of parallel neu 
ronal and glial cascades leading to functional impairment. 
Early in mid-life, initiating factors (e.g., reduced neuronal 
activity, onset of late-acting gene expression) induce doWn 
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regulation of neuronal (N) oxidative pho sphorylation trigger 
ing a cascade of impaired IEG signalling, biosynthetic poten 
tial, and critically, decreased capacity for neurite remodeling 
and synaptogenesis. In parallel, enhanced lipid metabolism 
and demyelination are triggered in oligodendrocytes (O) by 
altered energy metabolism or neural activity. In turn, astro 
cytes (A) hypertrophy and increase glycolysis of the glucose 
taken up by astrocytic endfeet on capillaries (C). Simulta 
neously, phagocytosis of myelin fragments triggers oxidative 
damage and in?ammatory responses in microglia (M). Even 
tually, the combined effects of reduced synaptic remodeling, 
decreased activity and axon conduction, altered extracellular 
matrix and expanding in?ammation result in cognitive failure 
and neuronal vulnerability. 
DETAILED DESCRIPTION OF THE INVENTION 
The concept of “biomarker” is Well-knoWn and useful con 
cept for those of skill in the genomic art. In general, a biom 
arker is a measurable biological manifestation that is a quan 
titative indication of the presence and degree of an underlying 
biological process of interest. 
We have devised a multi-stage method for the identi?cation 
of biomarkers for brain aging, using gene expression microar 
rays and behavioral testing. The method of the invention 
alloWs one skilled in the genomics art to identify both “aging 
and cognition-related genes” (ACGs) and unique genes that 
change With brain aging alone, based on formal statistical 
testing. 
As used in this speci?cation, the Word “cognitive” is 
de?ned as comprising the higher order intellectual/brain pro 
cesses involved in learning, including attention, acquisition, 
short-term memory, long-term memory and memory 
retrieval, among others. 
As used in this speci?cation, across different mammalian 
species, age de?nitions are as folloWs: “Young” mammals are 
those at or beyond reproductive maturity for the species. 
“Mid-aged” is de?ned in tWo Ways: at or around half the 
average lifespan for the species and at or around the midpoint 
betWeen reproductive maturity and average lifespan. “Aged” 
mammals are those at or around average lifespan. Animals 
intermediate betWeen tWo ages could be considered as part of 
the group to Which they are most closely chronologically 
related (With the exception of young animals, for Whom it 
Would be inappropriate to include prepubescent individuals) 
We used the bioinformatics and functional correlation 
strategy of the invention for microarray analyses. As a result, 
We Were able to detect multiple groups of related genes that 
Were altered by brain aging and also correlated With cognitive 
function across individual subjects. Most of the shifts in 
genomic regulation began by mid-life, Well before the onset 
of measurable cognitive impairment, implying that cognitive 
function is not altered substantially Without further progres 
sion and/or the cumulative effects of the initial changes in 
gene regulation. 
This analysis depended on a novel combination of three 
approaches for microarray research: (a) the quantitative mea 
surement of the dependent function of interest (cognitive 
performance), Which provided a basis for large-scale expres 
sion-function correlation analyses; (b) the application of for 
mal statistical analyses (ANOVA, Pearson’s) to large groups 
of independent microarray samples, Which conferred sub 
stantial statistical poWer and high detection sensitivity for 
even modest changes (loW false negative type II error); and c) 
systematic estimates of the maximum probabilities of false 
positives in our data. Our results using the method of the 
invention provide a generally comprehensive overvieW of 
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hippocampal genes/processes that are altered With brain 
aging and closely linked to brain functional decline. 
To verify the method of the invention, We ?rst tested young 
(3-4 months old), mid-aged (12-13 months old) and aged 
(24-25 months old) rats (n:9-10 per group) for performance 
on the Morris spatial Water maZe (SWM) and object memory 
task (OMT). Both behavioral tests clearly and reliably (sta 
tistically) revealed aging-related cognitive impairment (FIG. 
1). 
We then anesthetiZed (for euthanasia) all animals and dis 
sected out a region of the brain (CA1 region of the hippoc 
ampus) knoWn to be important for memory. These brain tis 
sues Were then prepared for analyses of gene expression 
pro?les (mRNA content) on Affymetrix GeneChip microar 
rays speci?c for the rat genome (RG-U34A arrays) (one array 
for each individual rat sample). The microarrays Were then 
read and analyZed for expression pro?le data on an Affyme 
trix GeneChip System according to the manufacturer’s 
instructions. 
The behavioral and microarray methods that Were used can 
reasonably be expected to apply as Well to mice as to rats. 
Similar behavioral and microarray methods knoWn to those of 
skill in the art can be used for testing of other mammals, 
including humans. The utility of the method of the invention 
for human testing is discussed beloW. 
We then transferred the data into standard computer 
spreadsheets (e.g., Excel) for performing statistical analyses 
of the effects of aging. Using Analysis of Variance (ANOVA) 
We de?ned the set of genes Whose degree of expression 
changed signi?cantly With brain aging. We then used that set 
of “Aging Genes” and tested each gene’s expression pro?le 
(across only the aged animals) for signi?cant correlation With 
memory performance on the Object Memory Task (OMT) as 
Well as the Morris spatial Water maZe (SWM). The “Aging 
Genes” Whose expression patterns correlated signi?cantly 
With cognitive performance Were de?ned as the primary sub 
set of “Aging and Cognition-Related Genes” (ACGs), and 
subcategoriZed as OMT-associated, SWM-associated, or 
both OMT and SWM-associated. We further included genes 
With no behavioral association that had an ANOVA p 
value§0.001 since genes identi?ed at this more stringent 
level are less subject to the error of multiple testing (FIG. 2, 
TABLES 1A and 1B). 
Based on those large-scale studies, We have developed a list 
of ACGs that appear to have considerable potential impor 
tance for assessing and generating neW treatments for age 
dependent functional decline (TABLES 1A and 1B). 
These lists contain some genes that Were identi?ed previ 
ously as being linked to brain aging or neurodegeneration 
(e.g., in?ammation or mitochondrial genes, Lee C K et al., 
Nature Genetics 25: 294-297 (2000)) but none has been pre 
viously shoWn to be speci?cally associated With both brain 
aging and aging-dependent cognitive impairment. Further, 
many genes on our list have not even been shoWn previously 
to be linked to brain aging alone or to cognition alone. Thus, 
our lists of ACGs are unique and useful biomarkers and thera 
peutic targets speci?cally for aging-dependent cognitive 
impairment. In addition, our list of all genes that change With 
brain aging contains many genes never before reported to 
change With brain aging, and therefore provides a useful and 
unique panel of gene biomarkers and therapeutic targets for 
study and treatment of brain aging. 
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In addition to these lists for identi?ed genes, We have also 
performed the same analyses and compiled the same lists for 
unidenti?ed expressed sequence tags (ESTs) that are on the 
same Affymetrix Chips (TABLE 2). These are valuable data, 
because once the ESTs are identi?ed, they can provide thera 
peutic targets. 
Using the method of the invention, We Were able to identify 
a number of processes and pathWays that previously have not 
been clearly associated With normal brain aging. The most 
unexpected ?ndings included altered expression pro?les sug 
gestive of increased myelin and lipid turnover, as Well as 
Widespread changes indicating coordinated doWnregulation 
of oxidative metabolism, decreased neurite outgroWth and 
synaptogenesis. Other novel genes We identi?ed appear to 
suggest alterations in general metabolic and biosynthetic 
chaperone functions. In addition, many of the identi?ed 
groups con?rmed previously described changes in expression 
for genes regulating several major processes (e.g., in?amma 
tion, glial reactivity, oxidative stress). HoWever, our results 
also extend the earlier ?ndings considerably by revealing the 
extent of the changes and the concurrent upregulation of 
potentially orchestrating transcription factors and cytokines 
that may provide important clues to pathogenic mechanisms. 
In order to begin to develop an integrative overvieW of 
potential interactions among the multiple altered expression 
patterns observed here, We considered functional implica 
tions at the pathWay level. Our interpretations rely on the 
functions that have been previously associated With many of 
the genes identi?ed by those of skill in the genomics art. 
These are identi?ed through PubMed literature searches, 
annotations provided by Affymetrix, entries in the SWissPro 
tein database and associations reported in the Genome Ontol 
ogy (GO). We also rely on the general assumption held by 
those of skill in the genomics art that similar changes in the 
expression of multiple genes of a particular pathWay imply 
like changes in the functions mediated by the encoded pro 
teins of that pathWay. Gene expression changes also can 
re?ect compensatory negative feedback regulation (or other 
dissociations of gene expression and protein function), but 
the potential confound of dissociation is presumably less of a 
problem in microarray analyses in Which multiple genes in a 
pathWay are observed to change in the same direction. Some 
of the primary metabolic pathWays and processes considered 
in the interpretations are depicted in TABLE 1. 
Functional Groups. We found age-dependent upregulation 
of many ACGs involved in in?ammatory/immune/ stress 
responses and doWnregulation of many involved in energy 
metabolism. In addition, We found alterations of gene expres 
sion re?ecting multiple categories/pathways not previously 
recogniZed to change With normal aging. These included 
upregulation of genes for myelin proteins, cholesterol bio 
synthesis and transport, amino acid metabolism, intracellular 
Ca2+ signaling, and protein processing, as strongly suggest 
ing an ongoing cycle of remyelination and demyelination. We 
also found Widespread doWnregulation of genes for biosyn 
thesis, immediate early responses, and synaptic structural 
plasticity, suggestive of neuronal involution. Multiple tran 
scriptional regulators and cytokines Were also identi?ed that 
may play orchestrating roles. Nearly all expression changes 
began by mid-life but cognition Was not impaired until late 
life. Upregulated genes for in?ammation and intracellular 
Ca2+ release Were among those most closely correlated With 
impairment. 
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TABLE 1A 
Functionally Grouped ACGs and Genes Showing 
Highly Signi?cant Age-Dependent Decreases in Expression 
SEQ ID NO: GenBank Description Young Mid Aged ANOVA p beh all 
Synaptic Structural Plasticity 
SEQ ID NO: 1 M64780* Agrn, Agrin 2746 r 105 2334 r 74 2207 r 79 0.0005 Both 
SEQ ID NO: 2 L21192 GAP-43, membrane attached signal 10324 1 546 8990 r 327 8165 r 480 0.0095 Both 
protein 2 (brain) 
SEQ ID NO: 3 S82649 Narp, neuronal activity-regulated 4358 r 300 3470 r 143 3247 r 185 0.0029 OMT 
pentraxin 
SEQ ID NO: 4 M74223 VGF, neurosecretory protein 6697 r 373 5836 r 387 4722 r 369 0.0042 OMT 
SEQ ID NO: 5 U63740* Fez1, Protein kinase C-binding 10339 1 180 9322 r 258 9388 r 330 0.0239 OMT 
protein Zeta1 
SEQ ID NO: 6 AB003726 Homerla, RuvB-like protein 1 3546 r 270 2354 r 121 2469 r 132 0.0001 None 
SEQ ID NO: 7 U19866 Arc, activity-regulated cytoskeleton- 6374 r 527 4408 r 228 4094 r 398 0.0008 None 
associated protein 
Transcription Regulator 
SEQ ID NO: 8 M18416 Egr1, Early groWth response 1 (Krox- 4911 r 259 3688 r 177 3544 r 165 0.0001 Both 
24) 
SEQ ID NO: 9 M92433 NGFI-C, Zinc-?nger transcription 2037 r 149 1576 r 44 1495 r 170 0.0009 Both 
factor 
SEQ ID NO: 10 L08595 Nuclear receptor subfamily 4, group 1467 r 80 1186 r 83 1011 r 62 0.0010 Both 
A, member 2 
SEQ ID NO: 11 AI030089 Nopp130, nucleolar phosphoprotein 471 r 31 397 r 31 314 r 22 0.0022 Both 
p130 
SEQ ID NO: 12 AF016387 RXRG, retinoid X-receptor gamma 1900 r 129 1503 r 95 1365 r 103 0.0059 Both 
SEQ ID NO: 13 AA800794 HT2A, Zinc-?nger protein 2480 r 67 2396 r 41 2097 r 73 0.0004 OMT 
SEQ ID NO: 14 AA799641 S164, Contains a PWI domain 7645 r 169 7690 r 183 6842 r 250 0.0106 OMT 
associated With RNA splicing 
SEQ ID NO: 15 U78102 Egr2, Early groWth response 2 576 r 95 223 r 21 205 r 23 0.0001 SWM 
SEQ ID NO: 16 U44948 SmLIM, smooth muscle cell LIM 1166 r 15 928 z 55 887 z 38 0.0001 SWM 
protein 
SEQ ID NO: 17 AA891717 USP-1, upstream stimulatory factor 1 3607 r 142 2993 r 91 3025 r 66 0.0003 None 
SEQ ID NO: 18 AF095576 Aps, adaptor protein With pleckstrin 526 r 40 275 r 49 272 r 46 0.0007 None 
and src homology 
Intracellular Signal Transduction 
SEQ ID NO: 19 AI176689 MAPKK 6, mitogen-activated protein 2012 r 84 1781 r 92 1528 r 88 0.0030 Both 
kinase kinase 6 
SEQ ID NO: 20 X89703 TPCR19, Testis Polymerase Chain 361 r 25 320 r 25 252 r 24 0.0155 Both 
Reaction product 19 
SEQ ID NO: 21 L04485 MAPPK1,mitogen-activated protein 13110 1 365 11951 1 312 11200 1 506 0.0104 OMT 
kinase kinase 1 
SEQ ID NO: 22 AA817892 Gnb2, Guanine nucleotide binding 6500 r 159 5606 r 214 5765 r 218 0.0110 OMT 
protein (beta 2subunit) 
SEQ ID NO: 23 AF000901 P58/P45, Nucleoporin p58 597 z 43 444 z 51 391 z 47 0.0150 OMT 
SEQ ID NO: 24 M87854 Beta-ARK-l, beta adrenergic 1994 r 110 1723 r 90 1544 r 114 0.0202 OMT 
receptor kinase 1 
SEQ ID NO: 25 AF058795 Gb2, GABA-B receptor 9443 r 360 9064 r 478 7857 r 323 0.0228 OMT 
SEQ ID NO: 26 AA800517 VAP1, vesicle associated protein 637 r 72 674 r 61 455 r 35 0.0228 OMT 
Signal Transduction 
SEQ ID NO: 27 AF003904 CRH-binding protein 773 z 51 782 z 35 630 z 23 0.0119 Both 
SEQ ID NO: 28 M15191 Tac1, Tachykinin 1415 :110 1078 r 57 1068 r 74 0.0093 OMT 
SEQ ID NO: 29 AF091563 Olfactory receptor 440 z 21 367 z 29 332 z 27 0.0233 SWM 
SEQ ID NO: 30 M64376 Olfactory protein 810 z 26 605 z 83 568 z 57 0.0247 SWM 
SEQ ID NO: 31 M15880 Npy, NeuropeptideY 4647 r 158 3561 r 223 3668 r 141 0.0004 None 
Adhesion, Extracellular Matrix 
SEQ ID NO: 32 M27207 Colla1, Procollagen-type I (alpha 1) 678 r 24 521 r 43 480 r 23 0.0005 Both 
SEQ ID NO: 33 AF104362 Omd, Osteomodulin (osteoadherin) 289 r 16 217 r 24 185 r 15 0.0024 Both 
SEQ ID NO: 34 D63886 MMP16, matrix metalloproteinase 16 664 r 23 604 r 37 542 r 19 0.0180 Both 
SEQ ID NO: 35 M21354 Col3a1, collagen type III alpha-1 203 z 22 157 z 13 132 z 9 0.0120 SWM 
SEQ ID NO: 36 AB010437 CDH8, Cadherin-8 163 z 24 100 z 12 83 z 17 0.0128 SWM 
Metabolism 
SEQ ID NO: 37 L03294 Lp1, lipoprotein lipase 1147 r 69 918 r 40 749 r 37 0.0000 Both 
SEQ ID NO: 38 S68245 Ca4, carbonic anhydrase 4 2272 r 75 1993 r 63 1825 r 54 0.0002 Both 
SEQ ID NO: 39 AA859975 LOC64201, 2-oxoglutarate carrier 4792 r 68 4370 r 102 4255 r 97 0.0010 Both 
SEQ ID NO: 40 M24542 RISP, Rieske iron-sulfur protein 10337 1 308 9095 r 327 8833 r 128 0.0013 Both 
SEQ ID NO: 41 M18467 Got2, glutamate oxaloacetate 9470 r 241 8355 r 179 8332 r 322 0.0061 Both 
transaminase 2 
SEQ ID NO: 42 X64401 Cyp3a3, Cytochrome P450-subfamily 805 r 64 762 r 51 581 r 34 0.0089 Both 
III (polypeptide 3) 
SEQ ID NO: 43 U83880 glycerol-3-phosphate dehydrogenase, 2054 r 73 1988 r 77 1673 r 111 0.0127 Both 
mitochondrial 
US 7,739,056 B2 
TABLE lA-continued 
Functionally Grouped ACGs and Genes Showing 
Highly Signi?cant Age-Dependent Decreases in Expression 
SEQ ID NO: GenBank Description Young Mid Aged ANOVA p beh all 
SEQ ID NO: 44 105499 GLS, glutaminase (mitochondrial) 915 r 24 844 r 44 787 r 14 0.0238 Both 
SEQ ID NO: 45 U90887 Arg2, arginase type II 499 z 21 374 z 31 364 z 22 0.0015 OMT 
SEQ ID NO: 46 M22756 Ndu?/2, mitochondrial NADH 12293 1 574 10193 1 670 9260 r 750 0.0134 SWM 
dehydrogenase (24 kDa) 
Transporters, Carriers 
SEQ ID NO: 47 L46873 Slc15a1, Oligopeptide transporter 426 r 30 411 r 24 292 r 27 0.0028 Both 
SEQ ID NO: 48 AB000280 PHT1, peptide/histidine transporter 802 z 20 659 z 40 691 z 37 0.0198 OMT 
SEQ ID NO: 49 U87627 MCT3, putative monocarboxylate 687 r 33 521 r 22 480 r 38 0.0002 SWM 
transporter 
SEQ ID NO: 50 AA799389 Rab3B, ras-related protein 353 z 21 324 z 25 251 z 23 0.0150 SWM 
Growth, Biosynthesis, Maintenance 
SEQ ID NO: 51 X16554 Prps1, Phosphoribosyl pyrophosphate 3159 r 81 2747 r 74 2637 r 97 0.0006 Both 
synthetase 1 
SEQ ID NO: 52 U66470 rCGR11, Cell growth regulator 820 z 31 676 z 31 662 z 38 0.0051 Both 
SEQ ID NO: 53 M37584 H2AZ, H2A histone family (member 5335 r 73 4906 r 186 4600 r 162 0.0090 Both 
Z) 
SEQ ID NO: 54 U90610 Cxcr4, CXC chemokine receptor 811 r 56 812 r 59 614 r 29 0.0109 Both 
SEQ ID NO: 55 AA874794 Bex3, brain expressed X-linked 3 16735 1 376 14986 1 588 14238 1 457 0.0047 OMT 
SEQ ID NO: 56 AA892506 coronin, actin binding protein 1A 4101 r 121 3625 r 114 3558 r 135 0.0104 OMT 
SEQ ID NO: 57 AA893939* DSS1, deleted in split hand/split foot 4201 r 76 3860 r 129 3658 r 141 0.0149 OMT 
protein 1 
SEQ ID NO: 58 AF087037 Btg3, B-cell translocation gene 3 652 r 55 676 r 71 460 r 29 0.0163 OMT 
SEQ ID NO: 59 U06099 Prdx2, Peroxiredoxin 2 12667 1 675 11742 1 641 10339 1 272 0.0216 OMT 
SEQ ID NO: 60 AI172476 Tieg-1, TGF-beta-inducible early 1127 r 99 925 z 63 812 z 53 0.0177 SWM 
growth response protein 1 
SEQ ID NO: 61 AA866411 Necdin, neuronal growth suppressor 1994 r 81 1568 r 86 1542 r 62 0.0005 None 
Protein Processing and Traf?cking 
SEQ ID NO: 62 X54793 Hsp60, heat shock protein 60 10088 1 333 9602 r 299 8693 r 229 0.0071 Both 
SEQ ID NO: 63 AA875047 TCPZ, T-complex protein 1 (Zeta 997 r 161 728 r 99 470 r 59 0.0095 Both 
subunit) 
SEQ ID NO: 64 D21799 Psmb2, Proteasome subunit (beta type 7298 r 242 6892 r 229 6395 r 177 0.0241 Both 
2) 
SEQ ID NO: 65 U53922 Hsj2, DnaJ-like protein (RDJ1) 10716 1 382 8836 r 190 8392 r 204 0.0000 SWM 
SEQ ID NO: 66 X78605 rab4b, ras-homologous (GTPase 3131 r 292 2040 r 196 2006 r 135 0.0012 None 
For TABLE 1A, “GenBank” is the gene accession number 
established at the web accessible GenBank database, The 
“Description” includes a ‘common name’ (if applicable) as 
well as a brief description of the gene product. Values for 
Young, Mid-Aged, and Aged categories are the meanzSEM 
of expression values. Genes are put into functional categories 
(see, above) and grouped by their level of association with 
behavior (expression correlated signi?cantly (Pearson’s; 
20.025) with both tasks, with the OMT, with the SWM, or 
with none of the tasks but highly signi?cant across age 
(20.001 on ANOVA across age, p>0.025 for correlation on 
both SWM and OMT). Within each level of association, 
genes are ranked by the signi?cance of the age-dependent 
change in their expression level (ANOVA; 20.025). Aster 
isked (*) genes are those that also showed a signi?cant behav 
ioral correlation (Pearson; 20.025). 
ACGs that were downregulated with aging (TABLE 1A) 
appeared primarily to represent metabolic and neuronal func 
tions (FIG. 3a). 
Metabolism. Multiple genes related to functions of the 
mitochondrial electron transport chain (e.g., glycerol 3 -phos 
phate dehdrogenase, NADH dehydrogenase, Rieske’s iron 
sulpher protein) were downregulated with aging (TABLE 
1A). Moreover, we found aging-dependent downregulation 
of several genes related to pathways important for glucogenic 
amino acid catabolism, including glutaminase and arginase 
(TABLE 1A). 
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Synaptic Structural Plasticity. One of the most prominent 
categories of identi?ed genes showing decreased expression 
and behavioral correlation was that comprising genes 
involved in synaptic structural plasticity, including neurite 
outgrowth and synaptogenesis (e.g., decreased expression of 
genes encoding agrin, GAP-43, Homer 1a, Narp, Arc, etc.) 
(TABLE 1A). Many of these genes are activity-dependent in 
neurons and have been linked previously to synaptic plastic 
ity, neurite remodeling or learning in univariate studies (e.g., 
Biewenga J E et al., Acia Biochim Pol 43: 327-38 (1996); 
Steward O et al., Neuron 21: 741-51 (1998), Mantych K B & 
Ferreira A, J Neurosci 21 : 6802-9 (2001 ), GuZowski J F et al., 
J Neurosci 20: 3993-4001 (2000), BeZakova G, et al. Proc 
Natl Acad Sci USA 98 9924-9 (2001)), although Gap-43 is 
one of the few reported so far to change with aging. Similarly, 
many other neural activity-dependent genes, including IEGs 
in the Transcription Regulators and Signaling categories 
(e.g., Egrl, Egr2, MAPKK, etc.), showed decreased expres 
sion with aging and were correlated with impaired cognition 
(TABLE 1A). 
In addition, multiple genes important for general growth 
and biosynthetic mechanisms, chaperone functions and pro 
tein processing were also downregulated with aging (e.g., 
hsp60, histone H2AZ, proteasome subunit, DNA J-like 
homolog, etc.) as were speci?c neuronal signaling genes 
(e.g., GluR 5-2, the kainate receptor; and neuropeptide Y) 
(TABLE 1A). These widely downregulated biosynthetic and 
signaling genes appear to re?ect a general involution of meta 
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bolic and neurite structural remodeling processes in neurons 
(e.g., FIG. 4, TABLE 1A). Chaperone proteins such as the 
DNA-J-like homolog and hsp60 play critical roles in preyent 
ing protein aggregates (Satyal S H et al., Proc Natl Acad Sci 
USA 97 5750-5 (2000)), Which are knoWn to be critical in 
AlZheimer’s disease (Price D L & Sisodia S S, Annu Rev 
14 
Neurosci 21: 479-505 (1998), Koyacs D M &TanZi R E, Cell 
M0! Life Sci 54: 902-9 (1998); Sisodia S S et al., Am JHum 
Genet 65: 7-12 (1999), TanZi R E & Parson A B (2000), 
Selkoe D J, Neuron 32: 177-80 (2001)), and could therefore 
have implications for age-dependent Vulnerability to AlZhe 
imer’s disease. 
TABLE 1B 
ACGs and Genes Showing Highly Signi?cant Age-Dependent Increases in Expression 
SEQ ID NO: GenBank Description Young Mid Aged ANOVA p beh all 
In?ammation, Defense, Immunity 
SEQ ID NO: 69 104488 Ptgds, Prostaglandin D synthase 3976 r 248 6891 r 350 8365 r 438 0.0000 Both 
SEQ ID NO: 70 X71127 Clqb, complement component l-q 885 r 52 1461 r 85 1895 r 102 0.0000 Both 
(beta polypeptide) 
SEQ ID NO: 71 103752 Microsomal GST-l, glutathione S- 368 r 43 695 r 60 910 r 45 0.0000 Both 
transferase 
SEQ ID NO: 72 L40362* MHC class I RT1.C-type protein 1755 r 64 2106 r 82 2501 r 77 0.0000 Both 
SEQ ID NO: 73 U17919 Aifl, allograft in?ammatory factor 1 712 r 29 990 r 47 1152 r 67 0.0000 Both 
SEQ ID NO: 74 M15562 MHC class II RT1.u-D-alpha chain 608 z 73 1194 r 238 2120 r 173 0.0000 Both 
SEQ ID NO: 75 X13044 Cd74, CD74 antigen —49 z 44 155 z 83 603 z 100 0.0000 Both 
SEQ ID NO: 76 M24324 RTS, MHC class I RT1 (RTS(u 3274 r 175 4599 r 363 5822 r 342 0.0000 Both 
haplotype) 
SEQ ID NO: 77 M32062 Fcgr3, Fc IgG receptor III (10W af?nity) 347 r 25 462 r 32 557 r 21 0.0000 Both 
SEQ ID NO: 78 AJ222813 I118, interleukin 18 110 z 33 208 z 14 261 z 16 0.0002 Both 
SEQ ID NO: 79 L40364 RT1AW2, RT1 class Ib 2033 r 126 2546 r 127 2842 r 115 0.0004 Both 
SEQ ID NO: 80 AI231213 Kangai 1, suppression oftumorigenicity 6 2727 r 116 2952 r 120 3484 r 139 0.0008 Both 
SEQ ID NO: 81 AI170268 Ptgfr, Prostaglandin F receptor 6651 r 248 8057 r 336 8502 r 359 0.0013 Both 
SEQ ID NO: 82 X52477 C3, Complement component 3 34 r 49 236 r 83 476 r 100 0.0034 Both 
SEQ ID NO: 83 X73371 FCGRZ, LoW af?nity immunoglobulin 218 z 19 285 z 24 384 z 21 0.0001 OMT 
gamma Fc receptor II 
SEQ ID NO: 84 X78848 Gstal, Glutathione-S-transferase (alpha 3145 r 74 3909 r 188 4155 r 204 0.0009 OMT 
typ?) 
SEQ ID NO: 85 AA818025* Cd59, CD59 antigen 6465 2 265 7269 2 163 7474 2 189 0.0052 OMT 
SEQ ID NO: 86 AA891810 GST, Glutathione S-transferase 1136 r 83 1411 r 70 1791 r 101 0.0001 SWM 
SEQ ID NO: 87 U92081 Gp38, Glycoprotein 38 547 z 26 679 z 38 802 z 66 0.0037 SWM 
SEQ ID NO: 88 X62322 Grn, Granulin 4514 r 145 4972 r 254 5375 r 119 0.0116 SWM 
Transcription Regulator 
SEQ ID NO: 89 X13167* NFl-A, nuclear factor 1 A 112 z 30 265 z 38 300 z 26 0.0008 Both 
SEQ ID NO: 90 U67082 KZF-l, Kruppel associated box 472 r 31 565 r 32 617 r 29 0.0099 Both 
(KRAB) Zinc ?nger 1 
SEQ ID NO: 91 U92564 RoaZ, Olf-l/EBF associated Zn ?nger 429 r 50 687 r 71 761 r 50 0.0014 OMT 
protein 
SEQ ID NO: 92 L16995 ADD1, adipocyte detenn/different- 784 z 100 1054 r 75 1179 r 95 0.0160 OMT 
dependent factor 1 
SEQ ID NO: 93 AI237535 LitaF, LPS-induced TNF-alpha factor 979 z 62 1078 r 68 1338 r 114 0.0193 OMT 
SEQ ID NO: 94 AI177161 Nfe212, NF-EZ-related factor 2 544 z 31 590 z 36 687 z 25 0.0096 SWM 
Signal Transduction 
SEQ ID NO: 95 U26356 S100A1, S100 protein (alpha chain) 1382 r 105 1636 r 75 1999 r 115 0.0008 Both 
SEQ ID NO: 96 AA850219 Anx3,Annexin A3 438 z 26 501 z 21 575 z 26 0.0023 Both 
SEQ ID NO: 97 D84477 Rhoa, ras-related homolog A2 749 r 108 1069 r 111 1319 r 85 0.0024 Both 
SEQ ID NO: 98 AF048828 VDAC1,voltage-dependent anion 2334 r 294 3157 r 392 3844 r 290 0.0137 Both 
channel 1 
SEQ ID NO: 99 AI102103 Pik4cb, Phosphatidylinositol 4-kinase 975 r 63 1029 r 67 1252 r 80 0.0247 Both 
SEQ ID NO: 100 L35921 Ggamma, GTP-binding protein (gamma 498 r 30 543 r 43 712 r 64 0.0108 SWM 
subunit) 
SEQ ID NO: 101 M83561 GluR-5, kainite sensitive glutamate 248 r 23 359 r 22 351 r 12 0.0007 None 
receptor 
Adhesion, Extracellular Matrix 
SEQ ID NO: 102 E13541 Cspg5, chondroitin sulfate proteoglycan 5 3938 r 342 5112 r 312 5980 r 242 0.0003 Both 
SEQ ID NO: 103 X83231 PAIHC3, Pre-alpha-inhibitor, heavy 2586 r 110 2974 r 180 3460 r 183 0.0038 OMT 
chain 3 
SEQ ID NO: 104 AF097593 Ca4, cadherin 2-type 1 (neuronal) 615 r 45 855 r 61 881 r 59 0.0049 OMT 
Myelin-Related Proteins 
SEQ ID NO: 105 M55534 Cryab, alpha crystalline polypeptide 2 2889 r 155 4153 r 196 4621 r 238 0.0000 Both 
SEQ ID NO: 106 D28111 MOBP, myelin-assocated 13950 1 386 15483 1 633 18407 1 909 0.0004 Both 
oligodendrocytic basic protein 
SEQ ID NO: 107 X06554 S-MAG, myelin-associated glycoprotein 5282 r 258 5595 r 140 65 64 r 326 0.0038 Both 
C-term 
SEQ ID NO: 108 S55427 Pmp, peripheral myelin protein 2458 r 59 2856 r 148 3080 r 129 0.0051 OMT 
SEQ ID NO: 109 M22357 MAG, myelin-assocated glycoprotein 978 r 163 1544 r 190 2455 r 332 0.0010 SWM 
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TABLE lB-continued 
ACGs and Genes Showing Highly Signi?cant Age-Dependent Increases in Expression 
SEQ ID NO: GenBank Description Young Mid Aged ANOVA p beh all 
Lipid Metabolism/Transport 
SEQ ID NO: 110 X54096 Lcat, Lecithin-cholesterol acyltransferase 187 r 35 298 r 30 417 r 38 0.0003 Both 
SEQ ID NO: 111 S83279 HSDIV, 17-beta-hydroxysterold 630 z 54 685 z 91 928 z 67 0.0182 Both 
dehydrogenase type IV 
SEQ ID NO: 112 U37138 Sts, Steroid sulfatase 368 z 74 521 z 33 587 z 35 0.0128 OMT 
SEQ ID NO: 113 X55572 Apod, Apolipoprotein D 5875 r 355 7281 r 601 8343 r 595 0.0133 OMT 
SEQ ID NO: 114 L07736 Cpt1a, Carnitine palmitoyltransferase 1 599 r 65 677 r 59 854 r 59 0.0192 OMT 
alpha (liver) 
Amino Acid/Transmitter Metabolism 
SEQ ID NO: 115 103481 DHPR, Dihydropteridine reductase 13260 1 369 16897 1 528 17432 1 380 0.0000 Both 
SEQ ID NO: 116 Z50144 Kat2, kynurenine aminotransferase II 106 r 33 183 r 19 240 r 24 0.0040 Both 
SEQ ID NO: 117 U07971 Transamidinase, mitochondrial 2897 r 130 3311 r 186 3644 r 182 0.0183 OMT 
SEQ ID NO: 118 M77694 Fah, fumarylacetoacetate hydrolase 847 r 36 990 r 49 1305 r 98 0.0002 SWM 
Cytoskeletal, Vesicle Fusion 
SEQ ID NO: 119 X62952 Vim, vimentin 571 z 100 998 z 162 1346 r 122 0.0016 Both 
SEQ ID NO: 120 AA892333 Tubal, alpha-tubulin —52 z 83 117 z 90 357 z 79 0.0080 Both 
SEQ ID NO: 121 U11760* Vcp, valosin-containing protein 4314 r 234 5004 r 333 5651 r 278 0.0120 Both 
SEQ ID NO: 122 U32498* RSEC8, rat homolog ofyeast sec8 —11 r 37 270 r 81 232 r 82 0.0236 OMT 
SEQ ID NO: 123 AF083269* P41-Arc, actin-related protein complex 406 r 23 488 r 49 626 r 72 0.0249 OMT 
1b 
SEQ ID NO: 124 AF028784 GFAP, glial ?brillary acidic protein 19860 1 714 19731 1 1002 23241 1 1058 0.0217 SWM 
Transporters, Carriers 
SEQ ID NO: 125 M94918 Hbb, beta hemoglobin 6172 r 737 8698 r 646 13715 1 1017 0.0000 Both 
SEQ ID NO: 126 U31866 Nclone10 3625 r 302 5416 r 561 7407 r 511 0.0000 Both 
SEQ ID NO: 127 D38380 Tf, Transferrin 11990 1 728 16431 1 707 19831 1 1519 0.0001 Both 
SEQ ID NO: 128 X56325 Hba1, alpha 1 homoglobin 14433 1 611 17259 1 959 23893 1 1426 0.0000 OMT 
SEQ ID NO: 129 AF008439 Natural resistance-associated 69 r 17 153 r 19 152 r 13 0.0018 SWM 
macrophage protein 2 
GroWth, Biosynthesis, Maintenance 
SEQ ID NO: 130 AA799645 FXYD domain-containing ion 1680 r 58 2025 r 68 2457 r 129 0.0000 Both 
transport regulator 1 
SEQ ID NO: 131 L03201 Ctss, cathepsin S 17087 1 393 19066 1 691 22376 1 875 0.0001 Both 
SEQ ID NO: 132 M27905 Rpl21, Ribosomal protein L21 11279 1 905 13999 1 389 15557 1 379 0.0001 Both 
SEQ ID NO: 133 AA893493 RPL26, Ribosomal protein L26 18442 1 688 23043 1 506 24252 1 1162 0.0001 Both 
SEQ ID NO: 134 X52619 Rpl28, Ribosomal protein L28 13167 1 323 13231 1 310 14520 1 228 0.0034 Both 
SEQ ID NO: 135 X14181* RPL18A, Ribosomal protein L18a 8623 r 430 10171 1 389 11025 1 602 0.0068 Both 
SEQ ID NO: 136 M31076 TNF-alpha, Transforming groWth 139 r 23 241 r 43 295 r 35 0.0167 Both 
factor (alpha) 
SEQ ID NO: 137 AI171462* Cd24, CD24 antigen 864 z 69 1270 r 86 1304 r 101 0.0026 OMT 
SEQ ID NO: 138 X68283 Rpl29, Ribosomal protein L29 9705 r 262 9500 r 300 10807 1 267 0.0050 OMT 
SEQ ID NO: 139 X53504* RPL12, Ribosomal protein L12 9877 r 328 11398 1 367 11719 1 620 0.0241 OMT 
SEQ ID NO: 140 U77829 Gas-5, groWth arrest homolog 173 r 15 228 r 14 264 r 20 0.0030 SWM 
SEQ ID NO: 141 AI234146 Csrpl, Cysteine rich protein 1 4436 r 335 4925 r 207 5451 r 179 0.0243 SWM 
Protein Processing and Traf?cking 
SEQ ID NO: 142 M32016 Lamp2, lysosomal-associated 759 r 38 906 r 36 1092 r 74 0.0008 Both 
membrane protein 2 
SEQ ID NO: 143 B01534 Rps15, Ribosomal protein S15 16577 1 368 17202 1 429 18363 1 368 0.0116 OMT 
SEQ ID NO: 144 AI028975 AP-I, adaptor protein complex (beta 1077 r 38 1163 r 69 1317 r 49 0.0158 OMT 
1) 
SEQ ID NO: 145 AI175486 Rps7, Ribosomal protein S7 5820 r 448 6409 r 312 7212 r 208 0.0215 OMT 
SEQ ID NO: 146 AF023621 Sort1, sortilin 414 z 34 813 z 143 812 z 109 0.0247 OMT 
SEQ ID NO: 147 AI230712 Pace4, Subtilisin ilike endoprotease 281 r 31 447 r 49 570 r 56 0.0010 SWM 
SEQ ID NO: 148 AA891445* Skd3, suppressor of K’“ transport 321 r 24 440 r 42 508 r 37 0.0043 SWM 
defect 3 
SEQ ID NO: 149 AF031430 Stx7, Syntaxin 7 794 :133 1387 r 188 1461 1122 0.0097 SWM 
SEQ ID NO: 150 AA900516 Pdi2, peptidyl arginine deiminase 57 r 42 314 r 62 344 r 51 0.0015 None 
(WPe 11) 
The analyses for TABLE 1B are as described for TABLE 
1A. 
Upregulated Genes. Genes that Were upregulated With 
aging and negatively correlated With behavior ?t primarily 
into categories that appeared to re?ect activated glial func 
tions (FIGS. 3B and 5, TABLE 1B). Additionally, among the 
60 
65 
main unexpected ?ndings Was a Widespread upregulation in 
the expression of genes encoding proteins for myelin synthe 
sis and lipid turnover (TABLE 1B). 
Lipid Metabolism. Multiple genes important for mitochon 
drial and cytosolic lipid [3-oxidation (e.g., carnitine palmi 
toyltransferase, lecithin-cholesterol acyltransferase, etc.; 
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TABLE 1B), the primary pathway for free fatty acid (FFA) 
catabolism, Were upregulated. 
Increased Myelin Synthesis, Cholesterol Biogenesis and 
Vesicle Transport. Importantly for identifying the trigger 
mechanism for elevated lipid catabolism, the expression of 
many genes encoding myelin-related proteins or myelin-re 
lated transcription factors on the microarray Was increased 
With aging (and several also Were correlated With cognitive 
impairment) (TABLE 1B). These observations strongly sug 
gest that a major increase in myelin synthesis programs devel 
oped With aging. This interpretation is also supported by the 
upregulation of multiple genes important in lipogenesis for 
cholesterol biosynthesis (Add 1/SREBP1), and the packag 
ing/transport of cholesterol esters and other complex lipids 
(ApoD, LCAT, etc.) (TABLE 1B). Recent studies have shoWn 
that stimulation of myelin synthesis programs in oligoden 
drocytes is associated With induction of genes for both myelin 
proteins and lipogenic pathWays (Nagarajan R et al., Neuron 
30 355-68 (2001)). 
Cyloskeleton/Vesicles. Moreover, expression of genes 
related to actin assembly, transport or fusion of packaged 
vesicles (actin related complex, rsec8, tubulin, and syntaxin 
7) Was increased (TABLE 1B). These molecules are associ 
ated With vesicle transport and fusion in neurons. In addition, 
hoWever actin assembly proteins are also knoWn to play a 
major role in myelin vesicle transport in oligodendrocytes 
(Madison D L et al., JNeurochem 72: 988-98 (1999)). Given 
the upregulation of myelin programs and the doWnregulation 
of synaptic plasticity genes, therefore, the age-dependent 
upregulation of genes linked to vesicle transport capacity 
seems more likely to be associated With enhanced myelin 
transport in oligodendrocytes. Further support for the vieW 
that extensive oligodendrocyte activation and/or synthesis 
occurs in hippocampal aging is provided by the observation 
that many genes that Were upregulated With aging are prefer 
entially expressed in oligodendrocytes (e. g., myelin proteins, 
FAH, PGD-S, etc.) (e.g., Labelle Y et al., Biochim Biophys 
Acza 1180: 250-6 (1993)). 
Myelin also is normally degraded to free fatty acids 
through the endosomal-lysosomal pathWay. Consistent With 
elevation of myelin degradation, We also found increased 
expression of Cathepsin S and other genes encoding lysoso 
mal enZymes (TABLE 1B). Cathepsin S is particularly impor 
tant in the processing of antigenic myelin fragments. 
Amino Acids. In contrast to enZymes for glucogenic amino 
acids (TABLE 1A), expression Was upregulated for multiple 
genes encoding enZymes related to the metabolism of the 
ketogenic/glucogenic amino acids, tyrosine, phenylalanine 
and tryptophan (e.g., DHPR, KAT, FAH, see, TABLE 1B). 
Catabolism of ketogenic amino acids yields either acetoac 
etate or one of its precursors (e.g., acetyl CoA), Which can be 
used either for energy metabolism or lipogenesis. Upregula 
tion of DHPR, Which catalyZes the formation of a critical 
cofactor (tetrahydrobiopterin) for tyrosine and monoamine 
synthesis, and concomitant upregulation of MAO-B (TABLE 
3), together suggest elevated metabolism of tyrosine and tryp 
tophan via greater monoamine turnover. 
In?ammation/ Defense/ Immunity. There Was massive 
upregulation of expression of genes encoding MHC class I 
antigen presenting molecules, and numerous other in?amma 
tory/immune proteins (TABLE 1B). Genes in the in?amma 
tion category exhibited some of the most robust monotonic 
changes With aging seen in our results using the method of the 
invention (e.g., most Were signi?cant at the p<0.001 criterion 
With 0.025 FDR) (TABLE 1B). Moreover, most Were 
inversely correlated With cognitive function (FIG. 3B). 
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Consistent With evidence of a role for oxidative stress in 
brain aging (Carney J M et al., Proc Natl Acad Sci USA 88: 
3633-6 (1991), Hensley K et al., Ann N YAcad Sci 786: 
120-34 (1996), Bickford P C et al., Brain Res 866: 211-7 
(2000), Lee C K, et al. Nat Genet 25: 294-7 (2000), Jiang C H 
et al., Proc NaZlAcad Sci USA 98: 1930-4 (2001)), We also 
found increased expression for molecules important in 
defense against oxidative stress (GST, GSTa1) (TABLE 1B). 
One potentially key neW ?nding here, as noted above, Was 
that DHPR Was upregulated With aging and correlated With 
cognitive decline (TABLE 1B). Its product, tetrahydrobiop 
terin, is also an essential cofactor for nitric oxide synthase 
(Boyhan A, et al. Biochem J 323 (Pt 1) 131-9 (1997)). 
Because oxyradicals formed from nitric oxide appear to play 
a major role in in?ammatory neuronal damage (Bal-Price A 
& BroWn G C, JNeurosci 21: 6480-91 (2001), Calingasan N 
Y & Gibson G E, Brain Res 885: 62-9 (2000)), this may be an 
important pathWay through Which the deleterious effects of 
in?ammation are mediated in brain aging. 
Glial Markers. Astrocyte reactivity and astrocyte markers 
are also Well recogniZed to increase in the aged rodent and 
human hippocampus (Land?eld P W et al., Science 214: 
581-4 (1981), Land?eld P W et al., JNeurobiol 23: 1247-60 
(1992), Nichols N R et al., NeurobiolAging 14: 421-9 (1993), 
Finch C E & Longo V D, Neuroin?ammalory Mechanisms in 
Alzheinier's Disease. Basic and Clinical Research, 237-256 
(2001)) and the present data con?rm extensive upregulation 
ofgenes (Finch C E & TanZi R E Science 278: 407-11 (1997)) 
for glial markers (e.g., vimentin, GFAP-cytoskeleton cat 
egory, TABLE 1B). In addition, We extended those observa 
tions to shoW that genes for proteoglycans (TABLE 1B) and 
other extracellular proteins (e. g., ?bronectin) that are compo 
nents of astroglial scars also Were upregulated. These changes 
may re?ect astroglial-mediated reorganiZation of the extra 
cellular matrix, a process knoWn to be unfavorable for axonal 
remodeling. 
Signal Transduction. Several genes in calcium regulating 
and G-protein-coupled signaling pathWays Were also identi 
?ed (TABLE 1B). In particular, S100A1, Which modulated 
Ca2+-induced Ca2+ release, and PI 4-kinase, Which acts to 
produce IP3 Were upregulated. Several other S100-related 
genes (e.g., S100A4 and P9K2; TABLE 3) Were also upregu 
lated With aging but failed to meet the strict criteria set forth 
herein (FIG. 2). 
Biosynthesis. Concomitantly, many ribosomal (groWth) 
and protein processing genes Were upregulated (TABLE 1B). 
The upregulated changes re?ect increased protein synthesis, 
turnover and phagocytosis associated With strongly elevated 
biosynthetic processes in glial compartments (e.g., elevated 
myelin, MHC, proteoglycan synthesis). 
Orchestrating Factors. Our data shoW that a number of 
transcriptional regulators and cytokines, including KZF-l, 
RoaZ and members of the NFI family (TABLE 1B) Were 
upregulated and therefore, may be strong candidates for coor 
dinating factors. Under some conditions, several of these 
factors function as negative transcriptional regulators. 
Relationship to Fold Change. The large majority of 
microarray analyses to date have used fold-change criteria to 
detect changes in expression. In addition to providing little 
basis for statistical assessment (e.g., Miller R A, et al. J 
Gerontol A Biol Sci Med Sci 56 B52-7 (2001)), hoWever, 
fold-change criteria are relative insensitive. Among the 139 
ACGs, most exhibited group mean fold changes betWeen the 
Young and Aged groups of less than 1.5 (92), a feW shoWed 
fold changes betWeen 1.5 and 2.0 (26), and only a handful of 
genes exceeded 2-fold-change (20) (TABLES 1A and B). 
Thus, feW of our results using the method of the invention 
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Would have been detected in the great majority of prior 
microarray studies, in Which 1.7 to 2-fold change cutoffs are 
commonly used as minimum criteria for identifying differ 
ences, and many changes are reported in the 3-4 fold range. 
Further, the rank order correlation betWeen group mean fold 
change and p values on the ANOVA for all aging-signi?cant 
genes, although signi?cant, Was modest according to Spear 
man’s correlation test (Spearman’s 1:045, p<0.001).Armit 
age P & Berry G, Statistical Methods in Medical Research, 
2'” Edn., 200-205 (1987). This indicates that fold-change 
accounted for only ~20% of the variance (r2) in the degree of 
statistical signi?cance on the ANOVA. Some of our results 
detected With the enhanced sensitivity of statistical analysis 
Were extremely subtle (e.g., 1.1 fold for the L28 and L29 
ribosomal proteins, TABLE 1B). Despite this enhanced sen 
sitivity, hoWever, numerous false negatives Were still 
undoubtedly present in our data set. 
Age Course of Gene Expression Changes. Using a design 
With three age groups enabled us to classify genes and cat 
egories according to their general patterns of age dependence 
of change (FIGS. 4 and 5). Genes Were classi?ed by Whether 
75% of the maximal change occurred betWeen theYoung and 
Mid-Aged groups (Y ng to Mid), the Mid-Aged and Aged 
groups (Mid to Aged), or theYoung and Aged groups (mono 
tonic). 
Almost all categories comprising doWnregulated and cog 
nitively correlated genes (TABLE 1A), exhibited their great 
est change betWeen the Young and Mid-Aged points, and 
many did not shoW much additional doWnregulation betWeen 
the Mid-Aged and Aged groups (FIG. 4). This Was also true 
for the entire population of genes Whose expression 
decreased With aging at p<0.025 (pie-chart inset, FIG. 4). 
Conversely, by far the largest fraction of functional categories 
of upregulated genes shoWed a monotonic age course of 
change that also began betWeen the Young and Mid-Aged 
points but, in addition, continued betWeen the Mid-Aged and 
Aged points (FIG. 5). HoWever, the Cytoskeletal and Tran 
scriptional Regulator categories contained signi?cant num 
bers of exceptions that exhibited >75% of their change 
betWeen the Young and Mid-Aged groups (TABLE 1B). 
Additionally, among all genes that shoWed signi?cant 
upregulation With aging, the majority ?t the monotonic clas 
si?cation (pie-chart inset, FIG. 5). Only a feW scattered genes 
shoWed a predominantly Mid to Aged change pattern (e.g., 
FIGS. 4 and 5 pie-charts). 
Strongest Correlations of PathWays With Memory Perfor 
mance. To determine Which pathWays Were most closely cor 
related With memory performance, We calculated the percent 
age of genes in each of our categories that Were correlated 
signi?cantly (at p<0.025) With both memory tests. We rea 
soned that each test measures aspects of memory but each test 
also has its oWn error sources and confounding contributions 
from non-cognitive performance factors. Therefore, genes 
that correlated With both tasks seem more likely to be asso 
ciated With cognitive processes. 
Because memory performance changed most betWeen the 
Mid-Aged andAged groups (FIG. 1), Whereas doWnregulated 
genes changed little (FIG. 4) and upregulated genes contin 
ued to increase (FIG. 5) betWeen those groups, the pattern of 
age course changes relative to cognitive performance Was 
more similar for upregulated than for doWn-regulated genes. 
Not surprisingly, therefore, more upregulated (52%) than 
doWnregulated (44%) genes Were correlated With perfor 
mance on both tasks. Three categories of doWnregulated 
genes had 50% or higher both-task correlations: Adhesion 
and extracellular matrix (3/5), Metabolism (8/10), and Pro 
tein processing and tra?icking (3/ 5). Whereas seven catego 
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ries of upregulated genes had 50% or higher both-task corre 
lations: Signaling (5/ 7), In?ammation (14/20), Cytoskeleton/ 
Vesicle (3/6), Myelin related proteins (3/5), Amino acid/ 
transmitter metabolism (2/4), Transporters and carriers (3/ 5), 
and GroWth, biosynthesis, maintenance (7/ 12). In the Signal 
ing category, moreover, genes involved in intracellular Ca2+ 
release, S100A1 and PI3-K (TABLE 1B), Were correlated 
With both tasks. 
Another Way to examine closeness of correlation speci? 
cally With memory impairment is to correlate gene expression 
With performance only in the aged group. This correlation 
focuses on variation in the performance of aged animals and 
removes the overall age course pattern from contributing to 
the correlation With impairment. This correlation is indepen 
dent of the ANOVA for aging effects and an FDR also can be 
calculated. Consequently, We tested each of the 139 primary 
aging- and behaviorally-related genes for correlation With 24 
hr memory performance on the OMT in the aged group. The 
OMT Was selected over the SWM for this test as it had the 
greater dispersion of performance needed for correlation 
analysis. The correlation tests in the aged group (n:10) of 
course had considerably less poWer than across all three 
groups (n:29) and the criterion for signi?cance Was set at 
p<0.025. 
Only 3 (4.9%) of the doWnregulatedACGs, but 10 (12.2%) 
of the upregulated ACGs Were correlated With Aged group 
performance on the OMT. The FDR for these genes Was 0.28. 
TWo of the 3 doWnregulated ACGs Were accounted for by the 
Synaptic Structural Plasticity category (Fez-1, agrin). For 
upregulated genes, tWo of the 10 ACGs Were from In?amma 
tion (MHC and CD59 antigen), three from Cytoskeleton/ 
Vesicle category (Vcp, rsec8 and p41-Arc), and three from 
Growth/Biosynthesis (2 ribosomal proteins and CD24 anti 
gen). No other category had more than one, including Tran 
scription (NFl-A) and Protein processing and tra?icking 
(Skd3). 
Thus, by the criterion of correlation on both tasks, the 
upregulated categories of In?ammation/immune, signaling 
(particularly Ca2+ signaling), Cytoskeleton/Vesicle and 
Amino Acid Metabolism Were ranked most highly. By the 
criterion of correlation in the aged group only, the upregu 
lated categories of Cytoskeleton/Vesicle (3/ 6), Biosynthesis 
(3/ 12) and In?ammation (2/20), and the doWnregulated cat 
egory of Synaptic Plasticity (2/7) Were ranked most highly. 
Bene?ts of the Invention. One of the major problems asso 
ciated With developing treatments for aging-dependent func 
tional decline is the lack of good genomic biomarkers or 
targets of brain aging needed for evaluating the e?icacy of 
different treatments. Our ACGs, therefore, could serve as 
excellent biomarkers of cognitive aging. Using microarrays 
constructed to contain oligonucleotide sequences speci?c for 
hybridization With and measurement of mRNAs of the iden 
ti?ed ACGs, laboratory animals could be assessed for degree 
of cognitive aging before, during and after treatment With a 
compound. Treatments that sloWed or reversed the ACG pro 
?le during aging might be highly promising for development 
as neW therapeutic approaches. Further, treatments that 
sloWed or reversed expression pro?les of particular genes in 
our panel of biomarkers might reveal Which speci?c genes 
among the subset of ACGs are most critical for the age 
dependent functional decline and, therefore, Would suggest 
genes and gene products that should be targeted With high 
priority for development of therapeutic interventions. The 
same approach could be applied using our panel of unique 
brain aging genes that are not speci?cally clustered With 
cognition related genes, to evaluate and develop neW thera 
pies and compounds for treatment of brain aging in general. 
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The panel of ACGs identi?ed here can be used on a 
microarray to perform diagnostic tests. Subjects suspected of 
having accelerated brain aging or early age-related neurode 
generative disease could provide a small brain biopsy sample 
for testing by microarray. This could then determine the sub 
ject’s suitability for pharmacologic intervention. 
Based on the gene lists described above, investigators can 
develop neW drugs or treatments aimed at altering the activity 
of one or more genes in the lists, or products encoded by those 
genes, or targets of the products, With the goal of counteract 
ing age-related cognitive impairment or brain aging in gen 
eral. 
A smaller subset of ACGs, speci?cally linked to some 
process or system (e.g., to in?ammation, mitochondrial func 
tion, or lipid metabolism, etc.), could be used in a microarray 
to test e?icacy of a neW compound targeted to sloWing or 
reversing aging and cognitive changes dependent on that set 
of genes or gene-impacted systems, either in experimental 
tests to develop neW compounds, or as diagnostic or thera 
peutic guides. 
Relevance to Human Brain Aging and AlZheimer’s Dis 
ease. Normal human brain aging is associated With memory 
dysfunction and appears to set the stage for AlZheimer’s 
disease and other age-related neurodegenerative conditions. 
It also shares many features With animal models of aging. 
Land?eld P W et al., JNeurobiol 23: 1247-1260 (1992). Thus, 
many of the memory-correlated gene expression pro?les seen 
here in rats may have implications for genomic mechanisms 
of human brain aging and/or AlZheimer’s disease. This vieW 
is supported by several parallels betWeen processes identi?ed 
here and those seen in human aging or AlZheimer’s disease. 
For example, myelin abnormalities are also found extensively 
in normal brain aging in humans (leukoaraiosis). These White 
matter changes in humans are also correlated With cognitive 
dysfunction and become more severe in disease states. Fur 
ther, cerebral metabolism begins to decline by mid-life in 
humans, much as it apparently does in rats (FIG. 4). Of 
particular note in light of our ?ndings on oxidative phospho 
rylation and myelin turnover, mitochondrial diseases in 
humans also can result directly in demyelination. 
It is interesting, in vieW of the apparently altered lipid 
metabolism seen here, that activity of the cholesterol ester 
synthesiZing enZyme acyl CoAzcholesterol acyltransferase 
(ACAT) is elevated in AlZheimer’s disease and appears 
directly coupled to amyloid production. ACAT has lipogenic 
functions someWhat similar to those of LCAT, Which Was also 
upregulated here (TABLE 1A). Moreover, activity of glyc 
erol-3-phosphate dehydrogenase (GPDH) is elevated in asso 
ciation With abnormal glucose metabolism in brains of 
patients With DoWn’s syndrome. The gene encoding this gly 
colytic enZyme Was also upregulated here (TABLE 1A). 
Other processes found in human aging orAlZheimer’ s disease 
brain for Which We found corollaries in gene expression 
include, as noted, in?ammation, oxidative stress and elevated 
KatII (kynurenine aminotransferase 2), among others. Thus, 
if these parallels depend, at least in part, on similar mecha 
nisms, our results shoW that Widespread genomic regulatory 
changes Would reasonably be expected to contribute to 
altered cerebral metabolism, lipid synthesis, neural activity 
and myelination in human brain aging as Well. 
Implications for a NeW Hypothesis of Brain Aging. Based 
on the functional implications of our results, as discussed 
above, We provide a neW Working model of brain aging (FIG. 
6). Early in adult life (i.e., before mid-life) a series of brain 
changes begin, perhaps initiated by neW expression of genes 
that exert deleterious late-life actions (e.g., “late genes”) 
(Finch C E, Longevity, Senescence and the Genome, 37-42 
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(Univ. Chicago Press, Chicago, 1990); Austad, S N, Why We 
Age. What Science Is Discovering about the Body's Journey 
Through Life (Indianapolis, Wiley, 1999)) or by catabolic 
hormonal processes (e.g., glucocorticoids, Porter N M & 
Land?eld P W, Nature Neurosci 1: 3-4 (1998)). These 
changes include reduced neuronal activity and induce a subtle 
shift from anabolic to catabolic metabolism in neurons. In 
neurons, the reduced anabolic capacity leads to diminished 
capacity for protein biosynthesis and, in particular, for activ 
ity-dependent neurite remodeling and synaptogenesis. Con 
comitantly, an increase in degradation of myelin and lipids 
begins, perhaps triggered by reduced neural activity, or 
reduced oxidative phosphorylation and/or demand for an 
alternative energy source, or by an immune process similar to 
multiple sclerosis, among other possibilities. The degenerat 
ing myelin fragments are endocytosed in micro glia and astro 
cytes, degraded by lysosomes and packaged into antigen 
presenting MHC molecules. This in turn activates 
orchestrating cytokines and transcription factors that trigger 
an in?ammatory reaction in the glia and possibly, in macroph 
ages. The in?ammation further accelerates the phagocytosis 
and degradation of myelin. As astrocytes hypertrophy, they 
increase glycolytic metabolism and synthesiZe “glial scar” 
proteins (e.g., ?bronectins, proteoglycans) that alter the 
extracellular matrix. In oligodendrocytes, lipogenic and 
myelin synthesis programs are activated in response to the 
ongoing demyelination and/or altered signaling pathWays. In 
turn, remyelination may increase demand for lipid substrate 
and thereby also accelerate demyelination. Thus, positive 
feedback cycles betWeen demyelination and myelination and/ 
or betWeen demyelination and in?ammation, among other 
processes, might develop and further drive cellular dysho 
meostasis. Eventually, the reduced synaptogenic capacity 
unfavorable extracellular matrix and degradative in?amma 
tory processes result in failure of cognitive processing. Addi 
tionally, the ongoing catabolic processes erode neuronal 
membranes and cytoskeletons, increase protein aggregation 
and enhance vulnerability to neurodegenerative disease. 
Accordingly, our results, in conjunction With this Working 
model, point directly to potentially useful therapeutic inter 
ventions and should, therefore, facilitate the design of such 
future therapeutics. 
The details of one or more embodiments of the invention 
are set forth in the accompanying description above. 
Although any methods and materials similar or equivalent to 
those described herein can be used in the practice or testing of 
the present invention, the preferred methods and materials are 
noW described. Other features, objects, and advantages of the 
invention Will be apparent from the description and from the 
claims. In the speci?cation and the appended claims, the 
singular forms include plural referents unless the context 
clearly dictates otherwise. Unless de?ned otherWise, all tech 
nical and scienti?c terms used herein have the same meaning 
as commonly understood by one of ordinary skill in the art to 
Which this invention belongs. All patents and publications 
cited in this speci?cation are incorporated by reference. 
The folloWing EXAMPLES are presented in order to more 
fully illustrate the preferred embodiments of the invention. 
These examples should in no Way be construed as limiting the 
scope of the invention, as de?ned by the appended claims. 
EXAMPLE 1 
Behavioral Results 
Thirty animals in three age groups (n:10/group) Were 
trained sequentially on tWo tasks, ?rst in the Morris spatial 
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Water maze (SWM) and then in the object memory task 
(OMT). Male Fischer 344 rats aged 4 months (Young, n:10), 
13 months (Mid-Aged, n:10) and 24 months (Aged, n:10) 
Were used. Overall, the training/testing lasted seven days, and 
hippocampal tissue Was collected 24 hr later. Training or 
testing occurred on each day except for the 2'” and 3rd days of 
the seven-day sequence. 
Methods used here for cognition assessment in the Morris 
Spatial Water MaZe (SWM), a task sensitive to both hippoc 
ampal function and aging, have been described previously 
Norris C M & Foster T C, Neurobiol Learn Mem 71, 194-206 
(1999). Brie?y, rats Were trained in a black tank, 1.7 M in 
diameter, ?lled With Water (27120 C.). Behavioral data Were 
acquired With a Columbus Instruments tracking system. After 
habituation to the pool, animals Were given cue training With 
a visible platform (?ve blocks of three trials, maximum of 60 
sec/trial, 20 sec intertrial interval and a 15 min interval 
betWeen blocks). Rats remained in home cages under Warm 
air after each block. Cue training Was massed into a single day 
and the criterion for learning Was ?nding the platform on 4 of 
the last 6 trials. For all animals that met this criterion, spatial 
discrimination training Was initiated three days later in Which 
the escape platform Was hidden beneath the Water but 
remained in the same location relative to the distal cues in the 
room. Fifteen min folloWing the end of spatial training, a 
1 -min duration free-sWim probe trial With the platform absent 
Was administered, during Which crossings over the former 
platform site (platform crossings) Were recorded to test acqui 
sition, folloWed by a refresher training block. Retention for 
platform location Was again tested 24-hr later using a second 
1-min free-sWim probe trial. 
During cue training in the SWM, all animals Were able to 
locate the visible escape platform according to our criteria 
and therefore, Were trained on the hidden platform spatial 
task. During acquisition, Aged animals performed more 
poorly (longer latencies) than Mid-Aged or Young. In addi 
tion, an aging-dependent decrease in 24 hr retention, mea 
sured by platform crossings (1-Way ANOVA, p<0.05), Was 
observed on the retention probe trial (FIG. 1A). Post hoc 
analysis indicated that Young and Mid-Aged animals exhib 
ited more platform crossings relative to Aged animals, but did 
not differ from each other. 
Methods used here for cognition assessment in the object 
memory task OMT) have been described previously by Enna 
ceurA & Delacour J, BehavBrain Res 31: 47-59. (1988). The 
object memory task (OMT) is also both sensitive to hippoc 
ampal function and affected by aging but is less dependent on 
physical strength and endurance. On the afternoon of the ?nal 
spatial maZe probe trial, animals Were administered a habitu 
ation session (15-min) in the empty mesh cage to be used for 
the OMT (63.5 cm><63 .5 cm). OMT training began 24 hr after 
habituation and consisted of a 15-min acquisition session 
during Which tWo 3 -dimensional objects Were placed at oppo 
site sides of the cage, folloWed by tWo 15-min retention test 
sessions at 1 and 24 hr posttraining. During the acquisition 
session, the cage contained tWo sample objects (A and B) and 
the time spent actively exploring each object Was recorded. 
After 1 hr, the rat Was reintroduced into the cage and the time 
spent exploring a novel object, C, relative to the familiar 
object, B, Was recorded. On the 24 hr test, familiar object A 
Was reintroduced and object B Was replaced by a second novel 
object, D. Objects Were randomiZed across individuals and 
timed measures of exploration Were used to calculate a 
memory index (Ml) as folloWs: Ml:(N—F)/T, Where N is time 
spent exploring the novel object, F is time spent exploring the 
familiar object, and T is total time spent exploring the tWo 
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objects. More time spent exploring the novel object (higher 
MI) is considered to re?ect greater memory retention for the 
familiar object. 
In the OMT, Aged animals performed as Well as Young or 
Mid-Aged on the 1 hr retention test (not shoWn), but there Was 
a signi?cant age-related decline in recall (1-Way ANOVA, 
p<0.001, for the main effect of age) on the 24 hr test (FIG. 
1B). At 24 hr, Young and Mid-Aged groups Were signi?cantly 
different from the Aged group, but not from one another 
(Young vs. Aged: p<0.001; Mid-Aged vs. Aged: p<0.05; 
Young vs. Mid-Aged: N.S., Tukey’ s post-hoc test; Armitage P 
& Berry G, Statistical Methods in Medical Research, 2'” 
Edn., 200-205 (1987)). 
EXAMPLE 2 
Gene Microarray Chip Results 
Microarray analyses Were performed on hippocampal CA1 
tissues from each of the same behaviorally characterized 30 
animals (one chip per animal), but one chip Was lost for 
technical reasons, leaving a data set of 29 microarrays 
(Y oung:9, Mid-Aged:10, Aged:10). For tissue preparation, 
tWenty-four hours after completion of the OMT testing, ani 
mals Were anesthetiZed With CO2 gas and decapitated. The 
brains Were rapidly removed and immersed in ice-cold, oxy 
genated arti?cial cerebrospinal ?uid consisting of (in mM): 
124 NaCl, 2 KCl, 1.25 KH2PO4, 2 MgSO4, 0.5 CaCl2, 26 
NaHCO3, and 10 dextrose. Hippocampi Were removed and 
the CA1 region from one hippocampus per animal Were dis 
sected by hand under a stereomicroscope. The CA1 tissue 
block from each animal Was placed in a microcentrifuge tube 
and ?ash froZen in dry ice for RNA isolation. 
For RNA isolation, total RNA Was isolated using the TRI 
ZOl reagent and folloWing the manufacturer’s RNA isolation 
protocol (Gibco BRL, #15596). One ml of TRlZol solution 
Was added to each tube containing the froZen tissue block and 
the tissue Was homogeniZed by 10 passages through an 181/2 
G syringe needle. After centrifugation, the RNA Was precipi 
tated from the aqueous layer, Washed and redissolved in 
RNase-free Water. RNA concentration and the integrity of 
RNA Were assessed by spectophotometry and gel electro 
phoresis. The RNA samples Were stored at —800 C. 
Gene expression analyses Were performed using the 
Affymetrix GeneChip System. The labeling of RNA samples, 
rat GeneChip (RG-U34A) hybridiZation and array scanning 
Were carried out according to the Affymetrix GeneChip 
Expression Analysis Manual (r.4.0, 2000). Each animal’s 
CA1 RNA Was processed and run on a separate rat gene chip. 
Brie?y, an average yield of 40 pg biotin-labeled cRNA target 
Was obtained from 5 pg of total RNA from each CA1 sample, 
of Which 20 ug cRNA Was applied to one chip. The hybrid 
iZation Was run overnight in a rotating oven (Affymetrix) at 
450 C. The chips Were then Washed and stained on a ?uidics 
station (Affymetrix) and scanned at a resolution of 3 pm in a 
confocal scanner (Agilent Affymetrix GeneArray Scanner). 
Each U34A rat chip (Affymetrix, Santa Clara, Calif.) con 
tained 8,799 transcript probe sets (gene representations). 
Although the measured signal intensity for a transcript probe 
set (Methods) re?ects mRNA content, it is referred to here as 
“gene expression”. HoWever, it is Well recognized that mRNA 
stability and other factors in addition to gene transcription can 
affect mRNA content. 
We used the microarray suite (MAS 4.0) softWare (Af 
fymetrix) to calculate the overall noise of the image (the 
amount of variation around the mean intensity, QraW) for 
each array. Overall noise Was highly similar across arrays in 
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all 3 age groups (Young: 21.8111.55; MidAged: 21.2512.24; 
Aged: 206612.06, N.S.). “All probe set scaling” Was used to 
set overall intensities of different arrays to an arbitrary target 
central intensity of 1500. Thus, the average intensity of each 
array Was adjusted to the 1500 value using a scaling factor 
(SF). There Was no signi?cant difference in SF across ages 
(Young: 1.5810.14; MidAged: 1.4610.20; Aged: 16310.16, 
N.S.). 
The algorithm used to determine Presence/Absence is 
listed in the Microarray Suite 4.0 Manual and is the basis 
upon Which a particular transcript is determined to be reliably 
detectable by a given probe set. Average difference scores, the 
average of the difference in expression intensity (ADEI) of 
each probe pair Within a probe set, formed the basis for 
determining expression (relative abundance) of transcripts, 
and throughout the text the term “expression level” refers to 
the ADEI score. When comparing across appropriately nor 
malized arrays, the larger the ADEI score, the greater the 
relative expression for that particular message. HoWever, 
ADEI scores are not comparable for relative expression levels 
among different messages on the same chip, as there are 
several other factors that can confound such an assessment 
(e. g., p. 356, Affymetrix Microarray Suite 4.0 User’s Guide). 
The Presence/Absence calls andAverage Difference scores 
for all probe sets on all 29 arrays Were then copied from the 
MAS pivot table to an Excel 9.0 (Microsoft, SR-1)Workbook. 
From Within Excel, the folloWing data manipulations Were 
performed. 
Min-Max. For the purposes of ?ltering (FIG. 2), each probe 
set Was normalized according to the formula: 
Where x is ADEI score, Xmin is the mean for the age group 
With the loWest ADEI score, and Ymax is the mean for the age 
group With the largest ADEI score. Thus, normalized mean 
values varied betWeen 0 (loWest) and 1 (highest) for each 
probe set. 
Standardization (Z-score): For the purpose of obtaining the 
mathematical means Within functional categories and graph 
ing, the data Was normalized using the Z-score method: 
Where X is the mean, and SD(x) is the standard deviation of 
ADEI across all age groups for an individual probe set. 
Statistical Analysis. All statistical tests Were performed 
using a combination Excel (Microsoft, version 9, SR-l) and 
Sigma Stat (SPSS, version 2). 
EXAMPLE 3 
Multi-Step Gene Identi?cation Algorithm 
The analytic algorithm of the invention, Which addresses 
the bioinformatics issues noted above, comprise three main 
steps aimed ?rst, at reducing the number of comparisons (to 
manage type I error), second, at reliably detecting modest 
aging differences With global statistical analyses (by 
ANOVA), and third, at identifying aging-related expression 
changes that Were quantitatively correlated With cognitive 
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function (by Pearson’ s test; Armitage P & Berry G Statistical 
Methods in Medical Research, 2”“ Edn., 200-205 (1987)) 
(see, FIG. 2). 
Multiple Comparison Reduction Step. The expected false 
positives in a series of multiple comparisons (false positive 
rate) are predicted to be a percentage of the total statistical 
comparisons to be made, as de?ned by the p-value (i.e., tests 
at p<0.05 Will on average generate 5% false positives). 
Accordingly, the absolute numbers of expected false positives 
can be decreased simply by reducing the total transcript sets 
that are tested in a microarray analysis. This can be done by 
deleting all transcripts identi?ed a priori as not likely to be 
relevant to the speci?c interests of the analysis. 
Using this step of the method, We reduced the total tran 
scripts to be tested in three phases. In the ?rst phase, We 
deleted quality control oligonucleotide sets (“control”, n:60) 
and all gene transcripts (probe sets) rated “absent” by our 
criteria. As used in this speci?cation, the term “quality control 
oligonucleotides” are those oligonucleotides and polypep 
tides used to test for the appropriate behavior of the techno 
logical system, rather than to measure expression levels of 
biological interest. 
Of the original 8,799 sets, 4,118 gene transcript sets Were 
removed at this stage, leaving 4,681 transcript sets that Were 
called “present” for further consideration (FIG. 2, step 1a). In 
the second phase, We deleted all “present” transcript sets 
representing “expressed sequence tags” (ESTs), Which have 
not yet been clearly linked to knoWn genes (FIG. 2, step 1b). 
There Were 1,213 such ESTs rated “present” that We ?ltered 
out in this phase, leaving 3,468 transcript sets for further 
consideration. The third reduction phase Was based on our 
interest in persistent aging-dependent changes re?ected in 
substantial differences betWeen the youngest and oldest 
groups. We further decreased the total transcript sets to be 
tested by deleting sets in Which the difference betWeen the 
Young and the Aged group did not comprise at least 75% of 
the maximum normalized difference among groups (i.e., in 
Which age-related changes from the Young baseline values 
Were maximal in the Mid-Aged group, but then reversed 
substantially (>25%) in the Aged group, possibly because of 
random, compensatory or developmental factors). There 
Were 1,483 sets removed by this criterion, retaining 1,985 
probe sets of the original 8,799 for formal statistical testing 
(FIG. 2; step 2). If the original 8,799 sets hadbeen tested at the 
p<0.025 alpha level, ~420 false positives Would have been 
expected. HoWever, by reducing the total number of sets to be 
tested for statistical signi?cance (at p<0.025), We reduced the 
absolute numbers of false positives expected from multiple 
tests, to ~50 (5% of 1985). 
Group Statistical Testing Step (ANOVA). In this second 
main step of the algorithm, each of the remaining 1,985 
transcript sets Was tested by 1-Way ANOVA for a signi?cant 
effect of aging (at p§0.025) across the 3 age groups (n:9— 
10/ group). Of the 1,985 tested sets, 233 Were found to change 
signi?cantly With aging (observed total positives). As noted, 
at p<0.025, approximately 2.5% (~50) of the 1,985 tested 
should be signi?cant by chance alone (expected false posi 
tives). In order to estimate the proportion of false discoveries 
anticipated among our 233 observed positives (i.e., the frac 
tion of observed positives expected to be false), We used the 
expected false positive value to calculate the false discovery 
rate (FDR) (Benjamini et al., Behav Brain Res 125: 279-284 
(2001)). For any multiple comparison, the false discovery rate 
provides an empirical estimate of the anticipated chance error 
rate among all positives detected. It is partly analogous to the 
p value of statistical tests, in that the false discovery rate 














